BTIG initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $90 price target. The firm sees Jasper’s briquilimab offering “an attractive pipeline in a product with compelling market potential” in addressing chronic urticaria, which it calls “a large lucrative market not well-served by available therapies,” as well as in severe asthma and in expansion indications, the analyst tells investors. The firm thinks briquilimab could be positively differentiated from Celldex’s (CLDX) barzolvolimab on safety, efficacy, and a more convenient and less frequent dosing regimen, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics initiated with a Buy at Stifel
- Jasper Therapeutics Board Changes and New Director’s Arrival
- Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
- Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
- Jasper Therapeutics presents data from preclinical briquilimab study